Literature DB >> 8630284

Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues.

X Chui1, H Egami, J Yamashita, T Kurizaki, H Ohmachi, S Yamamoto, M Ogawa.   

Abstract

The immunohistochemical expression of c-kit proto-oncogene product in 57 breast cancer tissues was studied using anti-c-kit proto-oncogene product antibody in comparison with 20 normal breast tissues and 58 benign breast tumours. In normal breast tissues, the c-kit proto-oncogene product was strongly expressed on cell membrane and/or cytoplasm of alveolar and ductal cells. The immunoreactive score (IRS) of c-kit proto-oncogene product in normal mammary epithelia was 6.22 +/- 2.11 (mean +/- s.d.). In benign breast diseases, the c-kit proto-oncogene product was detected heterogeneously with a reduced IRS (3.33 +/- 2.44). In breast cancer tissues, the expression of the immunoreactive c-kit proto-oncogene product was often deleted and the average IRS was significantly reduced compared to those of normal breast tissues or benign breast diseases tissues. Among benign diseases, the average IRS of intraductal papilloma was significantly reduced (1.34 +/- 1.70) and the staining intensity and pattern were found to be similar to those seen in breast cancer. The results in this study suggested that the c-kit proto-oncogene product is correlated with the growth control or the differentiation of normal breast epithelium. Also, the loss of the expression of this protein may indicate the change of the signal transduction in relation to malignant transformation in human mammary epithelium.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630284      PMCID: PMC2074515          DOI: 10.1038/bjc.1996.236

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor.

Authors:  P G Natali; M R Nicotra; A B Winkler; R Cavaliere; A Bigotti; A Ullrich
Journal:  Int J Cancer       Date:  1992-09-09       Impact factor: 7.396

2.  Transmembrane form of the kit ligand growth factor is determined by alternative splicing and is missing in the Sld mutant.

Authors:  J G Flanagan; D C Chan; P Leder
Journal:  Cell       Date:  1991-03-08       Impact factor: 41.582

3.  Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors.

Authors:  T Strohmeyer; S Peter; M Hartmann; S Munemitsu; R Ackermann; A Ullrich; D J Slamon
Journal:  Cancer Res       Date:  1991-04-01       Impact factor: 12.701

4.  Expression of c-kit receptor in normal and transformed human nonlymphoid tissues.

Authors:  P G Natali; M R Nicotra; I Sures; E Santoro; A Bigotti; A Ullrich
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

5.  Breast cancer is associated with loss of the c-kit oncogene product.

Authors:  P G Natali; M R Nicotra; I Sures; M Mottolese; C Botti; A Ullrich
Journal:  Int J Cancer       Date:  1992-11-11       Impact factor: 7.396

6.  Clonal analysis of human breast cancer by means of the polymerase chain reaction.

Authors:  S Noguchi; K Motomura; H Inaji; S Imaoka; H Koyama
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

7.  Clonal analysis of predominantly intraductal carcinoma and precancerous lesions of the breast by means of polymerase chain reaction.

Authors:  S Noguchi; K Motomura; H Inaji; S Imaoka; H Koyama
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

8.  Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase.

Authors:  A D Reith; C Ellis; S D Lyman; D M Anderson; D E Williams; A Bernstein; T Pawson
Journal:  EMBO J       Date:  1991-09       Impact factor: 11.598

9.  Embryonic RNA expression patterns of the c-kit receptor and its cognate ligand suggest multiple functional roles in mouse development.

Authors:  E Keshet; S D Lyman; D E Williams; D M Anderson; N A Jenkins; N G Copeland; L F Parada
Journal:  EMBO J       Date:  1991-09       Impact factor: 11.598

10.  Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family--oncogenic activation of v-kit involves deletion of extracellular domain and C terminus.

Authors:  F H Qiu; P Ray; K Brown; P E Barker; S Jhanwar; F H Ruddle; P Besmer
Journal:  EMBO J       Date:  1988-04       Impact factor: 11.598

View more
  27 in total

1.  Screening of the c-kit gene missense mutation in invasive ductal carcinoma of breast among north Indian population.

Authors:  Syed Rizwan Hussain; Sunil G Babu; Syed Tasleem Raza; Pradyumn Singh; Faisal Ahmed; Hena Naqvi; Farzana Mahdi
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

2.  c-kit (CD117) expression in human tumors and its prognostic value: an immunohistochemical analysis.

Authors:  Michael Medinger; Manuela Kleinschmidt; Klaus Mross; Barbara Wehmeyer; Clemens Unger; Hans-Eckart Schaefer; Renate Weber; Marc Azemar
Journal:  Pathol Oncol Res       Date:  2010-02-23       Impact factor: 3.201

Review 3.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

4.  Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.

Authors:  M Cristofanilli; P Morandi; S Krishnamurthy; J M Reuben; B-N Lee; D Francis; D J Booser; M C Green; B K Arun; L Pusztai; A Lopez; R Islam; V Valero; G N Hortobagyi
Journal:  Ann Oncol       Date:  2008-05-29       Impact factor: 32.976

5.  Up-regulation of Wnt7b rather than Wnt1, Wnt7a, and Wnt9a indicates poor prognosis in breast cancer.

Authors:  Jian Chen; Tian-Yu Liu; Hai-Tao Peng; Yan-Qing Wu; Li-Li Zhang; Xiao-Hong Lin; Yuan-Hui Lai
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

6.  Krüppel-like factor 5: a novel biomarker for lymph node metastasis and recurrence in supraglottic squamous cell laryngeal carcinoma.

Authors:  Xionghui Mao; Susheng Miao; Hongjiang He; Suping Miao; Rong Pei; Xianguang Yang; Chen Xiu; Kaibin Song; Jian Zhang; Ji Sun; Shenshan Jia; Qiang Guan
Journal:  Tumour Biol       Date:  2013-08-23

7.  Expression of c-kit proto-oncogene product in breast cancer tissues.

Authors:  Aydan Eroğlu; Aliye Sari
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

8.  Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.

Authors:  Dong-Ja Kim; Myung-Hoon Lee; Tae-In Park; Han-Ik Bae
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

9.  The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium.

Authors:  Eva Obermayr; Angelika Reiner; Burkhard Brandt; Elena Ioana Braicu; Alexander Reinthaller; Liselore Loverix; Nicole Concin; Linn Woelber; Sven Mahner; Jalid Sehouli; Ignace Vergote; Robert Zeillinger
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

10.  Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression.

Authors:  Masayuki Inoue; Kousaku Mimura; Shinichiro Izawa; Kensuke Shiraishi; Ayako Inoue; Shugo Shiba; Mitsuaki Watanabe; Takanori Maruyama; Yoshihiko Kawaguchi; Shingo Inoue; Tomonori Kawasaki; Aniruddha Choudhury; Ryohei Katoh; Hideki Fujii; Rolf Kiessling; Koji Kono
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.